Viewing Study NCT00913835

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:17 PM
Ignite Modification Date: 2025-12-31 @ 12:05 AM
Study NCT ID: NCT00913835
Status: COMPLETED
Last Update Posted: 2019-09-26
First Post: 2009-06-02
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
Sponsor: Eli Lilly and Company
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Ovarian Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Liposomal Doxorubicin View
None IMC-3G3 View
None 3G3 View
None Platinum resistant View
None Platinum refractory View
None Ovary View
None Neoplasm View
None PDGFr View